List of Excipients in Branded Drug PRAZIQUANTEL

Generic Drugs Containing PRAZIQUANTEL

Company	Ingredient	NDC	Excipient
Endo USA Inc	praziquantel	49884-231	CELLULOSE, MICROCRYSTALLINE
Endo USA Inc	praziquantel	49884-231	CROSCARMELLOSE SODIUM
Endo USA Inc	praziquantel	49884-231	HYPROMELLOSE 2208
Endo USA Inc	praziquantel	49884-231	MAGNESIUM STEARATE
Endo USA Inc	praziquantel	49884-231	POLYETHYLENE GLYCOL 1000

What are the Most Frequently-Used Excipients in PRAZIQUANTEL?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	HYPROMELLOSE 2208
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL 1000

Praziquantel Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Praziquantel has a large global treatment market but limited formulation differentiation in its conventional racemic tablet form. The strongest commercial opportunity is pediatric praziquantel, particularly an orally dispersible, low-volume dosage form that reduces tablet size, bitterness, swallowing difficulty, and dose-calculation errors. Excipient selection should prioritize taste masking, rapid dispersion, dose flexibility, chemical stability, and low-cost manufacture for mass drug administration programs.

The principal innovation opportunity is not a new active pharmaceutical ingredient. It is a better delivery system for praziquantel, including pediatric formulations, improved palatability, multiparticulates, modified dose strengths, and potentially formulations using the more active L-enantiomer, arpraziquantel.

What is the pharmaceutical formulation challenge for praziquantel?

Praziquantel is a poorly water-soluble anthelmintic used against schistosomiasis and several cestode infections. The marketed product is generally a racemic mixture containing D- and L-praziquantel. The L-enantiomer has substantially greater anthelmintic activity, while the D-enantiomer contributes strongly to bitterness and bulk dose.

The major formulation constraints are:

• Very bitter taste, particularly after tablet disintegration.
• Large dose requirements, often administered as multiple tablets.
• Low aqueous solubility.
• Limited suitability for young children who cannot swallow conventional tablets.
• Dose rounding problems because tablets are divided according to body weight.
• Need for stable products suitable for tropical climates.
• Low price expectations in public-health procurement.
• Limited tolerance for complex cold-chain or high-cost delivery systems.

WHO treatment recommendations commonly use praziquantel at weight-based doses, including 40 mg/kg for schistosomiasis in many programs. A formulation intended for infants and young children must accommodate doses that are much smaller than a conventional adult tablet while maintaining accurate content uniformity (World Health Organization [WHO], 2022).

What excipient strategy is appropriate for praziquantel tablets?

A conventional immediate-release tablet can use a low-cost combination of diluent, binder, disintegrant, lubricant, and taste-masking excipients. The formulation objective is rapid tablet breakup without releasing an intolerable bitter bolus in the mouth.

Recommended excipient functions

Formulation function	Candidate excipient classes	Commercial rationale
Dilution and compression	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Supports direct compression and dose uniformity
Taste masking	Polymer film coat, ion-exchange resin, lipid barrier, cyclodextrin complex	Reduces bitterness during chewing or dispersion
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Enables rapid dispersion and dissolution
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improves granule or tablet strength
Mouthfeel	Mannitol, xylitol, selected polyols	Improves sweetness and cooling sensation
Wetting and dissolution	Poloxamer, sodium lauryl sulfate at controlled levels	Improves wetting of poorly soluble particles
Lubrication	Magnesium stearate, sodium stearyl fumarate	Supports high-speed tableting
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or permitted colorants	Provides handling protection and partial taste masking

A mannitol-based orally dispersible tablet is commercially attractive because it gives a relatively clean mouthfeel, supports rapid disintegration, and is widely accepted in pediatric products. Lactose can reduce cost but may create constraints for specific patient populations and can contribute to a less favorable mouthfeel than mannitol.

Microcrystalline cellulose is useful for robust direct compression, but high levels can produce a chalky texture. Crospovidone is often suitable where rapid capillary action and low gelling are required. Croscarmellose sodium can provide strong swelling but needs optimization to avoid a viscous dispersion.

What formulations are protected by the strongest commercial opportunities?

The highest-value formulation concepts are those that address a clear clinical or procurement problem.

1. Orally dispersible pediatric tablets

A 150 mg or lower-strength dispersible tablet can support weight-band dosing and administration with a small amount of water. The product should disperse rapidly without requiring a spoonful of liquid or prolonged shaking.

Key development targets include:

• Disintegration in approximately one minute or less.
• Uniform dispersion in a small water volume.
• Low friability during distribution.
• Adequate hardness for packaging and transport.
• Acceptable taste after dispersion.
• Minimal sedimentation or particle aggregation.
• Compatibility with 40 mg/kg and other programmatic dosing schedules.

The commercial advantage is strongest in children below six years of age, where conventional tablets create swallowing and dose-splitting problems.

2. Taste-masked granules or pellets

Multiparticulate praziquantel can be delivered in sachets, sprinkle capsules, or dispersible granules. A polymer-coated pellet can separate praziquantel from taste receptors while allowing release after swallowing.

Potential coating systems include ethylcellulose, methacrylate copolymers, hypromellose, or lipid-based barriers. The coating must balance taste protection against rapid release. Excessive coating can delay dissolution and create regulatory concerns for an immediate-release product.

Granules also permit flexible weight-band dosing. The main risks are content uniformity, segregation, dose measurement, and packaging moisture protection.

3. Lipid-based or solubility-enhanced formulations

Praziquantel has low aqueous solubility, creating an opportunity for self-emulsifying drug delivery systems, amorphous solid dispersions, nanosuspensions, and cyclodextrin complexes.

These systems may improve dissolution and reduce dose size. Their limitations are cost, manufacturing complexity, excipient acceptability in young children, and potential instability under high temperature and humidity. A solubility-enhanced platform is more likely to succeed in private or institutional markets than in large-scale public-health procurement unless it produces a substantial reduction in dose burden or treatment failure.

4. Enantiomer-specific formulations

Arpraziquantel, the L-enantiomer, is under development as a pediatric treatment approach. Because the L-enantiomer is the more active component, an enantiomer-specific product could reduce the administered mass compared with racemic praziquantel. The formulation challenge shifts from simple taste masking to development of a stable, palatable, low-dose pediatric product with manufacturing economics suitable for endemic regions.

An L-praziquantel product could create a differentiated intellectual-property estate around:

• Enantiomer-specific composition.
• Particle engineering.
• Salt or solid-state form.
• Pediatric dosage form.
• Taste-masking technology.
• Manufacturing process.
• Weight-band dosing regimen.
• Combination treatment.

The commercial risk is that a new enantiomer must compete against a low-cost generic racemate and public-sector donation or procurement programs.

When does praziquantel lose exclusivity?

The original composition-of-matter and basic product exclusivity for praziquantel have expired. Praziquantel has been marketed for decades, and generic products are available internationally.

Asset	Sponsor or manufacturer	Regulatory position	Exclusivity assessment
Biltricide tablets	Bayer, historically marketed by Bayer affiliates	FDA-approved prescription product	Original exclusivity expired
Generic praziquantel tablets	Multiple manufacturers globally	Approved or registered in multiple jurisdictions	Compete primarily on price, supply, quality, and registration
Pediatric arpraziquantel programs	Pediatric praziquantel development consortia and commercial partners	Development-stage or jurisdiction-specific status	Potential new exclusivity for the specific active form and formulation

The commercial protection available today is more likely to come from formulation patents, manufacturing know-how, trademarks, regulatory exclusivity for a new pediatric product, and procurement contracts than from the old racemic praziquantel molecule.

What is the FDA regulatory status and Orange Book position for praziquantel?

Biltricide is an FDA-approved praziquantel product for specified parasitic infections. FDA approval does not confer continuing market exclusivity for the active ingredient because praziquantel is an established generic drug.

For a new product, regulatory classification would depend on the active form and formulation:

• A conventional racemic praziquantel tablet would generally face an abbreviated pathway if the reference product and applicable regulatory requirements support an ANDA.
• A materially different pediatric dosage form may require a 505(b)(2) application if it relies on existing praziquantel safety and efficacy information but introduces a new formulation, route, dosage form, or dosing approach.
• A new enantiomer, such as arpraziquantel, may require a more substantial clinical and chemistry, manufacturing, and controls package depending on FDA’s determination of its relationship to approved racemic praziquantel.
• A product for neglected tropical disease programs may qualify for regulatory incentives, priority review mechanisms, or pediatric development incentives if statutory criteria are met.

The Orange Book value of a new racemic formulation would depend on whether FDA accepts patent listings for the specific dosage form, formulation, or method of use. A basic excipient combination is unlikely to create strong protection unless it produces a specific, reproducible technical effect.

What patents protect praziquantel formulations?

The original praziquantel molecule is off patent in major markets. New protection is more defensible when claims focus on a technical feature rather than the general use of praziquantel.

Patentable subject matter with commercial relevance

1. Pediatric dosage forms
   Claims can cover dispersible tablets, granules, mini-tablets, sachets, or specific dose strengths.

2. Taste-masking systems
   Protection may cover a coated particle, polymer matrix, ion-exchange complex, lipid barrier, or multiparticulate architecture.

3. Solid-state and particle engineering
   Claims may target polymorphs, co-crystals, amorphous dispersions, particle-size distributions, or crystallization processes.

4. Solubility-enhancement systems
   Self-emulsifying compositions, nanosized praziquantel, cyclodextrin complexes, and polymeric dispersions can support composition claims.

5. Enantiomer-specific products
   L-praziquantel composition, formulation, and process claims can create a separate estate from legacy racemic praziquantel patents.

6. Manufacturing processes
   Continuous granulation, solvent-reduction methods, coating processes, and impurity-control methods can provide process protection even where composition claims are narrow.

7. Dosing regimens
   Weight-band dosing or pediatric administration methods may offer method-of-use protection, although enforcement and patentability vary by jurisdiction.

The strongest estate would combine composition claims, process claims, product-by-process limitations where appropriate, and method-of-use claims. A single broad claim covering "praziquantel with a taste-masking excipient" would face substantial prior-art risk.

How strong is the patent estate for a new praziquantel product?

A new praziquantel product can have moderate patent strength if it demonstrates a measurable technical advantage and uses a formulation architecture that is difficult to design around.

Stronger claim positions

• Specific coating thickness or polymer ratio linked to taste reduction and dissolution.
• Defined particle-size range producing rapid dissolution and dose uniformity.
• A pediatric tablet that disperses in a specified volume and time.
• A stable amorphous or enantiomer-specific solid form.
• A manufacturing process that consistently produces the claimed product.
• Clinical or sensory data showing superior palatability in children.
• Stability data under tropical climate conditions.

Weaker claim positions

• Generic use of mannitol, crospovidone, or hypromellose without a demonstrated effect.
• Broad claims covering any immediate-release praziquantel tablet.
• Claims limited to routine tablet excipients.
• Dosing claims that merely restate established praziquantel regimens.
• Formulations that are easily replicated through substitution of common polymers.

Patent strength should be assessed against prior art on praziquantel taste masking, dispersible tablets, pediatric anthelmintics, amorphous dispersions, and L-praziquantel development.

Which companies and organizations are developing improved praziquantel products?

The competitive field includes originator-linked manufacturers, generic drug companies, nonprofit product-development partnerships, and public-health agencies.

Commercial and development categories

Category	Representative participants	Competitive focus
Originator-linked products	Bayer and associated commercial entities	Established Biltricide supply and regulatory history
Generic manufacturers	Regional and global generic companies	Low-cost tablets, tenders, and country registrations
Pediatric development groups	Pediatric Praziquantel Consortium and partners	Orally dispersible or child-appropriate formulations
Enantiomer developers	Programs based on arpraziquantel	Lower-mass, pediatric-focused active form
Public-health institutions	WHO, UNICEF, national schistosomiasis programs	Procurement, treatment campaigns, and access

The pediatric segment is strategically different from the adult generic market. Buyers may value improved adherence and dosing accuracy, but procurement agencies remain highly price-sensitive. A successful product must combine clinical usability with a cost structure close to existing generic therapy.

What commercial opportunities exist for praziquantel excipients?

Excipient suppliers can capture value through platform products rather than praziquantel-specific ingredients. The most attractive opportunities are pre-engineered systems that reduce development time and improve regulatory acceptability.

High-potential excipient opportunities

Taste-masking platforms

A ready-to-use polymer or lipid coating system can support praziquantel pellets, granules, and mini-tablets. The value proposition depends on sensory performance, dissolution control, and compatibility with aqueous dispersion.

Direct-compression pediatric blends

A co-processed mannitol-cellulose-disintegrant blend could simplify manufacture of low-dose dispersible tablets. It must provide low segregation, adequate tablet strength, rapid dispersion, and acceptable mouthfeel.

Solubility-enhancement platforms

Amorphous solid-dispersion polymers, surfactant systems, and cyclodextrin-based technologies may improve dissolution. The commercial opportunity is greatest where the platform also improves dose uniformity or reduces tablet size.

Tropical-stability systems

Moisture-barrier excipients, protective coatings, desiccant-compatible packaging, and low-water-activity formulations can address distribution in Africa, Latin America, and South Asia.

Pediatric flavor systems

Sweeteners, flavors, and cooling agents must be selected for low-dose pediatric use and compatibility with the target markets. Excessive sweetness, strong flavor, or local regulatory restrictions can reduce acceptance.

What manufacturing and intellectual-property barriers affect praziquantel products?

The main manufacturing barriers are practical rather than molecule-specific.

Manufacturing risks

• Segregation in low-dose formulations.
• Poor content uniformity after blending or coating.
• Inadequate taste masking after tablet disintegration.
• Slow dissolution caused by excessive polymer coating.
• Moisture uptake during tropical storage.
• Tablet capping or friability at high compression speed.
• Dose loss during transfer of fine praziquantel particles.
• Difficulty scaling laboratory coating processes.
• Inconsistent particle size in nanosuspension or amorphous systems.

A product designed for mass drug administration should favor conventional equipment, aqueous or low-hazard processing, short production cycles, and packaging compatible with high-volume tender supply.

Geographic coverage

A patent and regulatory strategy should prioritize:

• United States.
• European Union and United Kingdom.
• Brazil and Mexico.
• South Africa.
• India.
• Egypt.
• Nigeria and other high-burden African markets.
• China and Southeast Asian markets where schistosomiasis or cestode disease creates demand.

Patent value will vary by market. In many endemic countries, procurement access, WHO prequalification, local registration, and manufacturing capacity may matter more than exclusionary patent rights.

What generic entry risks exist for a new praziquantel formulation?

A new racemic praziquantel formulation faces immediate substitution risk from existing tablets unless it delivers a clear benefit.

Generic entry scenarios

Scenario	Likely effect
Conventional adult tablet	Rapid price competition and limited differentiation
Low-dose pediatric dispersible tablet	Slower substitution if taste and dosing advantages are clinically meaningful
Taste-masked granules	Moderate protection if sensory performance is difficult to reproduce
Solubility-enhanced product	Potential differentiation, but higher cost may limit public-sector uptake
Arpraziquantel product	Separate competitive position, subject to clinical, regulatory, and manufacturing success
Combination product	Potentially stronger commercial position if it reduces treatment complexity

Paragraph IV litigation risk would be relevant only if a branded sponsor obtains Orange Book-listed patents for a new formulation or method of use. Legacy praziquantel products are unlikely to generate meaningful patent litigation because the core molecule and conventional tablet technology are no longer exclusive.

How does praziquantel compare with other neglected-disease drug opportunities?

Praziquantel has an unusually large public-health need but low active-ingredient exclusivity. Its commercial profile differs from newer neglected-disease products.

Attribute	Praziquantel	Newer neglected-disease product
Molecule exclusivity	Expired	May remain active
Pediatric need	High	Variable
Public procurement dependence	High	Often high
Formulation opportunity	High	Variable
Price tolerance	Low	Can be higher for novel therapy
Manufacturing complexity	Low to moderate	Moderate to high
Patent value	Concentrated in formulation and enantiomer	Often broader composition protection
Volume potential	Large	Usually smaller at launch

Praziquantel is attractive for companies with expertise in pediatric formulation, taste masking, high-volume manufacturing, public-sector tenders, and global regulatory submissions. It is less attractive for a strategy dependent on premium pricing for a standard racemic tablet.

What is the revenue exposure and market opportunity?

Praziquantel demand is driven by schistosomiasis control programs, veterinary use, private prescriptions, and treatment of cestode infections. The largest volume opportunity is pediatric schistosomiasis treatment, where conventional tablets are least suitable.

Revenue potential depends on:

• Number of children treated annually.
• Procurement price per treatment.
• Adoption by WHO-supported programs.
• Registration in endemic countries.
• Whether the product qualifies for donor or government procurement.
• Manufacturing cost per dose.
• Ability to supply large tenders without shortages.
• Whether the product uses racemic praziquantel or a higher-cost enantiomer.

A low-margin, high-volume product can produce attractive revenue if manufacturing yield, packaging, and tender execution are strong. A premium formulation that cannot meet public-sector pricing may be restricted to private markets and specialist use.

Key Takeaways

• Praziquantel’s original molecule and conventional product exclusivity have expired.
• The strongest commercial opportunity is a pediatric orally dispersible tablet, granule, or mini-tablet.
• Taste masking is the central formulation problem and the most practical source of differentiated value.
• Mannitol, microcrystalline cellulose, crospovidone, polymer coatings, and carefully selected flavor systems are leading excipient options.
• Solubility-enhanced systems offer technical differentiation but may be too expensive for mass drug administration.
• Arpraziquantel could create a new product category based on the more active L-enantiomer.
• Patent protection should combine composition, process, solid-state, dosage-form, and method-of-use claims.
• Public procurement, WHO-related access channels, tropical stability, and manufacturing cost will determine commercial success.
• A conventional racemic tablet has high generic-entry risk and limited premium-pricing potential.
• A pediatric product with demonstrated taste, dosing, and stability advantages has the strongest licensing and investment case.

FAQs

Can praziquantel be formulated as a liquid suspension?

Yes. A suspension can improve administration to young children, but it requires control of sedimentation, redispersibility, dose uniformity, microbial quality, and chemical stability. A dry powder for reconstitution may offer better shelf life than a ready-to-use liquid.

Which excipient is best for masking praziquantel bitterness?

No single excipient is universally optimal. Polymer-coated particles, ion-exchange systems, lipid barriers, and multiparticulate approaches generally provide stronger masking than simple sweetening. Sensory testing and dissolution testing must be evaluated together.

Is praziquantel suitable for an orally disintegrating tablet?

Yes, but the formulation must address dose size, bitterness, low solubility, tablet friability, and mouthfeel. A conventional high-dose tablet may be unsuitable for true oral disintegration without particle engineering or taste masking.

Could a praziquantel combination product receive stronger patent protection?

Potentially. A combination product may support composition, ratio, dosage-form, and treatment-regimen claims. Patent strength depends on novelty, unexpected therapeutic benefit, and the absence of obviousness based on known antiparasitic combinations.

What is the most defensible licensing asset in praziquantel?

A validated pediatric platform that combines taste masking, rapid dispersion, tropical stability, low manufacturing cost, and regulatory-ready data is likely more valuable than a routine excipient reformulation. An enantiomer-specific product could command greater strategic interest but carries higher development and regulatory risk.

References

Bayer Healthcare Pharmaceuticals Inc. (2017). Biltricide (praziquantel) prescribing information. U.S. Food and Drug Administration.

Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. U.S. Department of Health and Human Services.

Pediatric Praziquantel Consortium. (2024). Pediatric praziquantel development program. https://www.pediatricpraziquantelconsortium.org/

World Health Organization. (2022). WHO guideline on control and elimination of human schistosomiasis. World Health Organization.

World Health Organization. (2023). WHO prequalification of medicines programme: Finished pharmaceutical products. World Health Organization.